金银花防治西妥昔单抗引起的皮肤毒性反应的临床研究

摘要
图/表
参考文献(26)
相关文章 (14)

全文: PDF (0 KB) HTML (40 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨金银花液湿敷对西妥昔单抗引起的皮肤毒性反应的预防和治疗效果。方法选取2016年7月～2018年4月南方医科大学深圳医院及中山大学附属第八医院的60 例接受西妥昔单抗联合化疗的结直肠癌初治患者作为研究对象，采用1∶1 比例随机将其分为试验组（30 例）和对照组（30 例）。试验组全程给予金银花液湿敷，4 次/d，对照组仅在发生Ⅲ度及以上皮肤毒性反应给予金银花液湿敷，单盲法观察记录两组皮肤毒性反应的发生情况。比较各级皮肤毒性反应的例数、发生时间、缓解比例。结果试验组的整体皮肤毒性反应的严重程度低于对照组，差异有统计学意义（P＜0.05）。在首次出现Ⅱ度皮肤毒性反应后，试验组中皮肤毒性反应不再继续加重的比例高于对照组，差异有统计学意义（P＜0.05）。试验组首次出现Ⅱ度皮肤毒性反应的时间[（23.8±3.8）d]长于对照组[（15.1±3.2）d]，差异有统计学意义（P＜0.05）；试验组中出现Ⅱ度皮肤毒性反应后不再继续加重的比例（68.2%）高于对照组（33.3%），差异有统计学意义（P＜0.05）；试验组和对照组Ⅲ度及以上皮肤毒性反应经金银花液湿敷治疗后得到缓解的比例（分别为71.4% 和72.7%），差异无统计学意义（P＞0.05）。结论金银花液湿敷可能对西妥昔单抗引起的皮肤毒性反应有较好的预防和治疗效果，但尚需大样本研究。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	杜永丽
	罗丹谷
	谭志博
	何家玲

关键词 ：金银花, 西妥昔单抗, 皮肤毒性反应, 临床研究

Abstract：Objective To evaluate the effect of Honeysuckle in preventing and curing skin toxicity induced by Cetuximab. Methods From July 2016 to April 2018, 60 patients with colorectal cancer treated by Cetuximab Plus chemotherapy in Shenzhen Hospital of Southern Medical University and the Eighth Affiliated Hospital of Sun Yat-sen University were selected as subjects, and randomly divided into experimental group (30 cases) and control group (30 cases) in a 1∶1 ratio. The experimental group was given Honeysuckle 4 times per day during the whole process, while Honeysuckle was administered in the control group only after the occurrence of skin toxicity of grade Ⅲor above. Single-blind method was used to record the occurrence of skin toxicity in two groups.The number of cases in each grade of skin toxicity,the occurrence time, the alleviation proportion in two groups were compared. Results The severity of skin toxicity in the experimental group was lower than that in the control group,the difference was statistically significant (P＜0.05). After the first second degree of skin toxicity，the proportion of skin toxicity in the experimental group that did not continue to aggravate was higher that in the control group, the difference was statistically significant (P＜0.05). The occurrence time of grade Ⅱskin toxicity in the experimental group([23.8±3.8]days)was longer than that in the control group([15.1±3.2]days),and the differences were statistically significant (P＜0.05）. The proportion of patients suffering from grade Ⅱskin toxicity that has not deteriorated in the experimental group (68.2%) was higher than that in the control group (33.3%), and the differences were statistically significant (P＜0.05）.The alleviation proportion of grade Ⅲskin toxicity or above in expe rimental group and control group (71.4% and 72.7% respectively) was statistically insignificant (P＞0.05）.Conclusion Honeysuckle may have a good effect on prevention and treatment of skin toxicity induced by Cetuximab, but it needs further studies with large samples.

Key words： Honeysuckle Cetuximab Skin toxicity Clinical trial

基金资助:广东省深圳市宝安区医疗卫生科研项目（2016CX 310）

通讯作者: 罗丹谷（1982-），女，广东茂名人，本科，主管护师，护士长，研究方向：肿瘤临床与护理

作者简介: 杜永丽（1981-），女，四川泸州人，本科，主管护师，研究方向：肿瘤护理工作

引用本文:

杜永丽；罗丹谷；谭志博；何家玲. 金银花防治西妥昔单抗引起的皮肤毒性反应的临床研究[J]. 中国当代医药, 2019, 26(9): 214-217转231.
DU Yong-li； LUO Dan-gu； TAN Zhi-bo； HE Jia-ling. Clinical study on the prevention and treatment of Honeysuckle in skin toxicity induced by Cetuximab. 中国当代医药, 2019, 26(9): 214-217转231.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2019/V26/I9/214

[1]	Chen W，Zheng R，Baade PD，et al.Cancer statistics in China，2015[J].CA Cancer J Clin，2016，66（2）：115-132.
[2]	Brenner H，Kloor M，Pox CP.Colorectal cancer[J].Lancet，2014，383（9927）：1490-1502.
[3]	Bokemeyer C，Van Cutsem E，Rougier P，et al.Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer： pooled analysis of the CRYSTAL and OPUS randomised clinical trials[J].Eur J Cancer，2012，48（10）：1466-1475.
[4]	Bokemeyer C，Bondarenko I，Makhson A，et al.Fluorouracil，leucovorin，and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer[J].J Clin Oncol，2009，27（5）：663-671.
[5]	Maughan TS，Adams RA，Smith CG，et al.Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer： results of the randomised phase 3 MR COIN trial[J].Lancet，2011，377（9783）：2103-2114.
[6]	Chen D，Li L，Zhang X，et al.FOLFOX plus anti-epidermal growth factor receptor（EGFR）monoclonal antibody（mAb）is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer：a meta-analysis[J].Medicine（Baltimore），2018，97（10）：e0097.
[7]	Folprecht G，Hamann S，Schutte K，et al.Dose escalating study of cetuximab and 5-FU/folinic acid （FA）/oxaliplatin/irinotecan （FOLFOXIRI） in first line therapy of patients with metastatic colorectal cancer[J].BMC Cancer，2014，14：521.
[8]	Price TJ，Peeters M，Kim TW，et al.Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer （ASPECCT）：a randomised，multicentre，open-label，non-inferiority phase 3 study[J].Lancet Oncol，2014，15（6）：569-579.
[9]	Pinto C，Barone CA，Girolomoni G，et al.Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy[J].Oncologist，2011，16（2）：228-238.
[10]	杨欣，李洪波，陈诚，等.金银花药性与功效的文献考证[J].中国实验方剂学杂志，2010，16（18）：220-222.
[11]	邓霁玲.金银花的药理作用研究与实际临床应用分析[J].医药前沿，2017，7（2）：284-285.
[12]	王亚琼，陈卫，钟水生，等.金银花清热解毒作用的血清代谢组学研究[J].中药材，2016，39（5）：1129-1133.
[13]	张海霖，王国蓉，张仕碧，等.金银花液热湿敷防治放疗加西妥昔单抗致皮肤反应的效果观察[J].中华护理杂志，2010，45（4）：307-310.
[14]	龙小丽，黄艳，庞凡.金银花煎液外敷治疗西妥昔单抗致痤疮样皮疹[J].护理学杂志，2011，26（9）：34.
[15]	杨剑霞，孙丽凯.复方金银花煎液湿热敷联合夫西地酸乳膏外用治疗分子靶向药物所致皮疹的效果观察[J].护理学报，2015，22（2）：61-62.
[16]	容怡英，何湘子，丘小芬，等.金银花联合玫瑰果油治疗爱必妥致皮肤毒性反应的效果观察[J].护理学报，2010，26（S1）：155.
[17]	戎煜明，丘惠娟，林晓平，等.中药内服加金银花外用治疗西妥昔单抗引起的痤疮样皮疹[J].中药材，2017，40（10）：2472-2474.
[18]	武惠丽，李毅，宁晓云，等.复方金银花煎液湿热敷与夫西地酸乳膏联合治疗靶向药物所致皮疹的临床疗效[J].现代生物医学进展，2017，17（27）：5258-5261.
[23]	庞瑞.金银花有效成分的药理学研究进展[J].陕西中医学院学报，2011，34（3）：77-79.
[19]	World Medical Association.World Medical Association Declaration of Helsinki：ethical principles for medical research involving human subjects[J].JAMA，2013，310（20）：2191-2194.
[20]	Nardone B，Nicholson K，Newman M，et al.Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 （HER1）and HER1/2 inhibitors in cancer patients[J].Clin Cancer Res，2010，16（17）：4452-4460.
[21]	CunninghamD，HumbletY，SienaS，etal.Cetuximabmonotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer[J].N Engl J Med，2004，351（4）：337-345.
[22]	Lacouture ME，Lai SE.The PRIDE （Papulopustules and/or paronychia，regulatory abnormalities of hair growth，itching，and dryness due to epidermal growth factor receptor inhibitors）syndrome[J].Br J Dermatol，2006，155（4）：852-854.
[24]	张百霞，周凤琴，郭庆梅.金银花中黄酮类化合物的研究进展[J].中国实验方剂学杂志，2012，18（23）：2013-2014.
[25]	陈继明，洪超群.金银花药理作用分析[J].亚太传统医药，2013，11（5）：43-44.
[26]	Lee GH，alietzis G，Askari A，et al.Is right-sided colon cancer different to left-sided colorectal cancer?-a systematic review[J].Eur J Surg Oncol，2015，41（3）：300-308.